Write in a clean editor, then format for The Journal of Prevention of Alzheimer s Disease in one click — DocuGuru applies the official Springer Nature template with superscript references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.
The Journal of Prevention of Alzheimer s Disease is a peer-reviewed journal published by Springer Nature, covering Dementia and Cognitive Impairment Research, Alzheimer's disease research and treatments, Nutritional Studies and Diet.
| Publisher | Springer Nature |
|---|---|
| Reference style | Superscript numbered (Nature) Superscript — small raised numerals in the text 1. Smith, A., Jones, B. & Lee, C. A representative article title. The Journal of Prevention of Alzheimer s Disease 12, 45–58 (2023).
Formats any DOI in The Journal of Prevention of Alzheimer s Disease style. No sign-up. |
| Publishes research in | Dementia and Cognitive Impairment Research Alzheimer's disease research and treatments Nutritional Studies and Diet Health Systems, Economic Evaluations, Quality of Life Cancer-related cognitive impairment studies |
| ISSN | 2274-5807 |
| Citation impact (2-yr) | 5.79 |
| h-index | 63 |
| i10-index | 474 |
| Total citations | 22,453 |
| Open access | Yes |
| Top institutions publishing here | Inserm |
| Journal website | www.springer.com |
| You get | A submission-ready PDF and the editable LaTeX source — ready to submit. |
Citations each year’s papers have accumulated so far — the most recent years are still building up.
BACKGROUND: Alzheimer's disease is a progressive, irreversible, and fatal disease for which accumulation of amyloid beta is thought to play a key role in pathogenesis. Aducanumab is a human monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta. OBJECTIVES: We evaluated the efficacy and safety of aducanumab in early Alzheimer's disease. DESIGN:…
Lecanemab (Leqembi®) is approved in the United States for the treatment of Alzheimer's disease (AD) to be initiated in early AD (mild cognitive impairment [MCI] due to AD or mild AD dementia) with confirmed brain amyloid pathology. Appropriate Use Recommendations (AURs) are intended to help guide the introduction of new therapies into real-world clinical practice.…
Mild Alzheimer's disease is the leading cause of dementia, accounting for 50-70% of cases. Alzheimer's disease is an irreversible neurodegenerative disease, which affects daily life activities and social functioning. As life expectancy increases and demographic ageing occurs, the global prevalence of Alzheimer's disease is expected to continue to rise especially in developing countries, leading to…
Alzheimer's disease is a progressive, irreversible neurodegenerative disease impacting cognition, function, and behavior. Alzheimer's disease progresses along a continuum from preclinical disease, to mild cognitive and/or behavioral impairment and then Alzheimer's disease dementia. Recently, clinicians have been encouraged to diagnose Alzheimer's earlier, before patients have progressed to Alzheimer's disease dementia. The early and accurate detection…
Scientific evidence collected over the past 4 decades suggests that a loss of cholinergic innervation in the cerebral cortex of patients with Alzheimer's disease is an early pathogenic event correlated with cognitive impairment. This evidence led to the formulation of the "Cholinergic Hypothesis of AD" and the development of cholinesterase inhibitor therapies. Although approved only…
